Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy
Cette étude analyse l'intérêt de stratégies utilisant des nanomatériaux pour améliorer l'efficacité des thérapies anticancéreuses basées sur l'immunogénicité des cellules mortes
Immunogenic cell death (ICD) is emerging as a key component of antitumor therapy that harnesses the immune system of the patient to combat cancer. In recent years, several efforts were made to improve the ICD-based therapies. Here, we discuss how nanomaterial-based strategies increase the efficacy of ICD and highlight their benefits and challenges.
Trends in Cancer , résumé, 2024